FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us

Resources

  • Videos
  • Research Reports
  • FAQ

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
SpyGlass Pharma, Inc. Common Stock Stock AnalysisComprehensive stock analysis for SpyGlass Pharma, Inc. Common Stock (SGP) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisSGP
SGP
SpyGlass Pharma, Inc. Common Stock
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
SGP
Home🔹Stocks🔹SpyGlass Pharma, Inc. Common Stock

SpyGlass Pharma, Inc. Common Stock

SGP•NASDAQ

SpyGlass Pharma, Inc. Common Stock

SGP•NASDAQ
Market cap
$830.82M
Sentiment

Your view on SGP

Mkt Cap
$830.82M
Sentiment
Your view
SGP
SpyGlass Pharma, Inc. Common Stock
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
SGP
Company Overview

Overview

What the company does, where it operates, and who runs it.

About SpyGlass Pharma, Inc. Common Stock

Industry
Biotechnology
Sector
Healthcare
CEO
Patrick H. Mooney
Headquarters
27061 Aliso Creek Road, Aliso Viejo, CA, US
Industry
Biotechnology
Sector
Healthcare
CEO
Patrick H. Mooney
Headquarters
27061 Aliso Creek Road, Aliso Viejo, CA, US
Description

SpyGlass Pharma, Inc. is an advanced biopharmaceutical company dedicated to developing innovative therapeutic approaches for individuals suffering from chronic eye conditions. Its flagship investigational product, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), is engineered for implantation during standard cataract removal procedures with the aim of reducing elevated intraocular pressure (IOP) in patients afflicted with either open-angle glaucoma (OAG) or ocular hypertension (OHT). Co-founded in January 2019 by Malik Y. Kahook and Glenn Sussman, the company maintains its headquarters in Aliso Viejo, CA.

FRC Research

Media

Infographics, videos, and posts covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

FRC's fair value estimate for SpyGlass Pharma, Inc. Common Stock, and the rating behind it. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Valuation, profitability, liquidity and leverage ratios for SpyGlass Pharma, Inc. Common Stock. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Dividend history, yield and payout sustainability for SpyGlass Pharma, Inc. Common Stock. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Reported vs. expected earnings history for SpyGlass Pharma, Inc. Common Stock. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Income statement, balance sheet and cash flow history for SpyGlass Pharma, Inc. Common Stock. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

SpyGlass Pharma, Inc. Common Stock valued side by side against its closest peers. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Which institutions hold SpyGlass Pharma, Inc. Common Stock, and how their positions are changing. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

Insider Trading

Recent buying and selling by company executives.

Buying and selling by SpyGlass Pharma, Inc. Common Stock executives and directors. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

U.S. Senate disclosures naming SpyGlass Pharma, Inc. Common Stock. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.

House Trading

U.S. Representative disclosures filed under the STOCK Act.

U.S. House of Representatives disclosures naming SpyGlass Pharma, Inc. Common Stock. Representatives' reported transactions in this security, shown next to the company's fundamentals.

News

Latest headlines and market coverage.

Latest headlines and company announcements for SpyGlass Pharma, Inc. Common Stock. Press releases and market coverage, newest first.

News

Latest Market News